Product Program year 2025 Source: CMS Open Payments

Vyloy

Drug Oncology

NDC 0469-3425-10

Open in the dashboard

General payments

$1,345,600

9,201 payments

Research payments

$1,612,797

373 payments

Through program year 2025, $1,345,600 in general payments and $1,612,797 in research payments were reported against Vyloy (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2025 General $1,126,374 7,688
2025 Research $1,484,914 305
2024 General $219,225 1,513
2024 Research $127,883 68

Breakdown

Who paid General payments · program years 2024–2025
  1. Astellas Pharma US Inc $1,083,417 8,971 payments
  2. Astellas Pharma Global Development $146,118 167 payments
  3. Astellas Pharma Europe Ltd $116,064 63 payments
Top recipients General payments · program year 2025
  1. Ronan Kelly Medical Oncology · Dallas, TX $91,694 8% · 56 payments
  2. Maen Abdelrahim Medical Oncology · Houston, TX $85,740 8% · 66 payments
  3. Farshid Dayyani Medical Oncology · Orange, CA $79,056 7% · 48 payments
  4. Amit Mahipal Medical Oncology · Rochester, MN $60,368 5% · 39 payments
  5. Ben George Medical Oncology · Rochester, MN $42,656 4% · 33 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Medical Oncology Internal Medicine $576,810 53% · 490 practitioners
  2. Hematology & Oncology Internal Medicine $198,575 18% · 1,414 practitioners
  3. Anatomic Pathology & Clinical Pathology Pathology $91,709 8% · 46 practitioners
  4. Nurse Practitioner $50,051 5% · 367 practitioners
  5. Internal Medicine $32,510 3% · 106 practitioners

The top 5 of 76 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $264,516 23% · 375 recipients
  2. California $241,937 21% · 451 recipients
  3. Minnesota $138,444 12% · 9 recipients
  4. Tennessee $98,430 9% · 232 recipients
  5. Florida $56,889 5% · 542 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

9,201 general · 373 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record